The gross sales is at Rs 98,142 million
Sun Pharmaceutical Industries has reported financials for the third quarter ending December 31 2021. In Q3FY22, the consolidated sales from operations at Rs 98,142 million, growth of 11 per cent over Q3 last year. The India formulation sales has been registered at Rs 31,676 million, up 15 per cent over same quarter last year, the US formulation sales is at $397 million, growth of 6 per cent over Q3 last year. The emerging markets formulation sales is at $239 million, up by 17 per cent over Q3 last year. The Rest of World formulation sales is at $181 million, up by 3 per cent over the same quarter last year. The R&D investment is at Rs 5,471 million compared to Rs. 5,595 million for Q3FY21. The EBITDA at Rs 25,574 million, up by about 8 per cent over Q3 last year, with an EBITDA margin of 26.1 per cent. The net profit for the quarter was at Rs 20,588 million, up 11 per cent YoY.
In 9mFY22, the consolidated sales from operations at Rs 290,403 million, showing a growth of 17 per cent over the same period last year. The India formulation sales is at Rs 96,637 million, up by 26 per cent over 9m last year. The US formulation sales is at $1,138 million up by 15 per cent over 9m last year. The Emerging Markets formulation sales is at $700 million up by 19 per cent over 9m last year. The Rest of World formulation sales is at $554 million, up by 12 per cent over 9m last year. The EBITDA is at Rs 78,900 million up about 27 per cent over 9m last year, with EBITDA margin at 27.2 per cent. Excluding the exceptional items, the adjusted net profit for 9mFY22 was at Rs 60,851 million, up about 33 per cent YoY. The reported net profit for 9mFY22 was at Rs 55,500 million compared to Rs 20,097 million for 9m last year.
Dilip Shanghvi, MD, Sun Pharma said, “We achieved a sustained momentum and good growth across businesses; despite rising costs, we have achieved higher profitability. Our India business continues to grow faster than the market, leading to an increase in market share. Our global speciality business for the first nine months has already crossed previous full-year revenues. We remain steadfast in our focus on topline growth, operational efficiencies and business continuity while simultaneously continuing to expand our global speciality presence.”
